Cargando…
Trial-based Cost-effectiveness Analysis of an Immediate Postoperative Mitomycin C Instillation in Patients with Non–muscle-invasive Bladder Cancer
BACKGROUND: Bladder cancer imposes a significant public health burden on the European Union. There is a need for cost-effective treatment and follow-up regimens. OBJECTIVE: To assess the cost-effectiveness of immediate mitomycin C (MMC) instillation within 1 d after surgery compared to delayed MMC i...
Autores principales: | Hentschel, Anouk E., Blankvoort, Christian J., Bosschieter, Judith, Vis, André N., van Moorselaar, R. Jeroen A., Bosmans, Judith E., Nieuwenhuijzen, Jakko A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883187/ https://www.ncbi.nlm.nih.gov/pubmed/35243387 http://dx.doi.org/10.1016/j.euros.2021.12.008 |
Ejemplares similares
-
SPTAN1, APC, and FGFR3 Mutation Status and APOBEC Mutation Signatures are Predictive of Mitomycin C Response in Non-muscle-invasive Bladder Cancer
por: Lindgren, Maria Skydt, et al.
Publicado: (2021) -
Quality of Life in Patients with High-grade Non–muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial
por: van Straten, Christine G.J.I., et al.
Publicado: (2023) -
Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation
por: Hentschel, Anouk E., et al.
Publicado: (2022) -
A systematic review on mutation markers for bladder cancer diagnosis in urine
por: Hentschel, Anouk E., et al.
Publicado: (2020) -
Partial Versus Complete Bacillus Calmette-Guérin Intravesical Therapy and Bladder Cancer Outcomes in High-risk Non–muscle-invasive Bladder Cancer: Is NIMBUS the Full Story?
por: Rezaee, Michael E., et al.
Publicado: (2021)